Mode
Text Size
Log in / Sign up

Polypoidal choroidal vasculopathy

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for polypoidal choroidal vasculopathy

7 trials tracked for polypoidal choroidal vasculopathy: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 314 citations.

7Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 4 Phase 2 3
  1. Phase 4 Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) Completed · 314 cited
  2. Phase 4 An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Completed · 20 cited
  3. Phase 4 Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy Completed
  4. Phase 4 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed
  5. Phase 2 Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy Completed
  6. Phase 2 Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) Completed
Show 1 more trials
  1. Phase 2 Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Polypoidal choroidal vasculopathy: what the trials found

Ranibizumab treatment for polypoidal choroidal vasculopathy (PCV) demonstrated significant improvements in visual outcomes. Patients showed a mean increase of 8.3 letters in Best Corrected Visual Acuity (BCVA) at 12 months (p<0.001), with 115 patients achieving complete polyp regression by that same time point (p<0.0001) 1.

Aflibercept is established as an intervention for PCV, with studies evaluating both standard administration and a 'Treat and Extend' regimen [2, 3]. Clinical data for aflibercept showed a mean improvement of 9 letters in visual acuity from baseline to 12 months, with 87.5% of patients losing fewer than 15 letters and 95% maintaining a visual acuity of at least 20/200 3.

Verteporfin Photodynamic Therapy (PDT) was evaluated for PCV, with results showing that 15, 18, and 9 participants achieved at least one complete polyp regression during a 6-month period as assessed by ICGA 4.

Recent results — preliminary, needs further review

  • High-dose ranibizumab is currently being evaluated in Phase 2 trials 6.
  • Comparative studies on ranibizumab dosing (0.5 mg vs. 2.0 mg) are ongoing to determine the impact on safety and efficacy 5.
  • Low-dose ranibizumab (0.3 mg vs. 0.5 mg) is also under investigation in Phase 2 trials 7.

For the clinician treating this condition

  • Ranibizumab is effective for PCV, showing significant mean gains in BCVA and high rates of complete polyp regression at 12 months 1.
  • Aflibercept is an established option, with high rates of vision maintenance and improvement over 12 months 3.
  • Verteporfin PDT is an established intervention for inducing polyp regression 4.

AI synthesis of 6 cited trials, updated Oct 5, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.